Story
Braveheart Bio Files for US IPO, Seeks Up to $318.8 Million
Braveheart Bio, a clinical-stage biopharmaceutical company, has filed for an initial public offering in the United States, aiming to raise up to $318.8 million. The company plans to list its shares on the Nasdaq Global Market, according to a press release.
Offering Details
The proposed offering consists of 18,750,000 shares at an indicative price range of $15.00 to $17.00 per share. At the top end of this range, the IPO would reach its maximum target. Upon a successful listing, the company's stock will trade under the ticker symbol BRVE.
Underwriters and Market Implications
AdA syndicate of prominent investment banks is managing the deal. The underwriters listed in the filing include Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor.
For investors, the IPO represents a new opportunity in the speculative biopharmaceutical sector. Proceeds from such offerings are critical for clinical-stage companies, typically used to fund expensive research and development, advance drug candidates through multi-phase clinical trials, and prepare for potential commercialization.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.